http://rdf.ncbi.nlm.nih.gov/pubchem/reference/33504718

Outgoing Links

Predicate Object
contentType Journal Article|Review
endingPage 292
issn 1179-1942
0114-5916
issueIdentifier 5
pageRange 283-292
publicationName Drug Safety
startingPage 283
bibliographicCitation Andresen V, Hollerbach S. Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome? Drug Saf. 2004;27(5):283–92. doi: 10.2165/00002018-200427050-00001. PMID: 15061683.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_56c2765a12219f21e17fcf8dbd7d5bde
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5743a6a4bc1a12ce1a3fa320f603e7f6
date 200404
identifier https://doi.org/10.2165/00002018-200427050-00001
https://pubmed.ncbi.nlm.nih.gov/15061683
isPartOf https://portal.issn.org/resource/ISSN/1179-1942
https://portal.issn.org/resource/ISSN/0114-5916
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1481
language English
source https://scigraph.springernature.com/
https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome?
discusses http://id.nlm.nih.gov/mesh/M0240025
http://id.nlm.nih.gov/mesh/M0003364
http://id.nlm.nih.gov/mesh/M0019685
http://id.nlm.nih.gov/mesh/M0244242
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7811
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2099
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5202
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7507
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10792

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129095671
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID46506274
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128322882
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3359

Total number of triples: 35.